Objective: The objective of the study was to profile leukocyte markers modulated during intravenous immunoglobulin (IVIg) treatment, and to identify markers and immune pathways associated with clinical efficacy of IVIg for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) with potential for monitoring treatment efficacy. 
| INTRODUCTION

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
is an immunologically heterogeneous autoimmune inflammatory disease resulting in peripheral nerve demyelination, causing profound disability in more than 50% of cases (Franssen & Straver, 2014; Mathey et al., 2015) . High-dose intravenous immunoglobulin (IVIg), with a superior safety profile to steroids (Dalakas, 2012) , is a preferred first-line treatment with established evidence of efficacy (Hughes et al., 2008) . The kinetics of response to IVIg in CIDP is similar to plasma exchange (Dalakas, 2012) and is faster than that reported for corticosteroids (Van den Bergh et al., 2010) . Short-term prednisolone or pulsed dexamethasone may induce long-term remission (Eftimov, Vermeulen, van Doorn, Brusse, & van Schaik, 2012) , whereas IVIg does not eliminate the underlying cause of disease and ongoing IVIg is required to prevent relapse. Individual optimization of IVIg dosing is required because of individual rates of IgG catabolism in order to achieve a pharmacokinetic profile supporting treatment efficacy (Kuitwaard et al., 2013; Rajabally, Wong, & Kearney, 2013) .
To accommodate patient-specific metabolism of IVIg, early highdose IVIg is recommended for initial recovery followed by titration to the minimal effective dose (Mathey & Pollard, 2013) , whereas low-dose initial treatment may be insufficient to prevent irreversible axonal loss in some CIDP variants (Dalakas, 2011 (Dalakas, , 2012 Mathey & Pollard, 2013) . However, there are no definitive strategies to predict the optimal IVIg dose nor the response to treatment, suggesting frequent monitoring is required to establish optimal treatment in new patients.
Immunomodulatory effects of IVIg have been observed across diverse leukocyte populations, including immunopathogenic disease pathways characteristic of CIDP (Dalakas, 2011; Ephrem et al., 2005; Mathey & Pollard, 2013; Mathey et al., 2015) . Based on preliminary phenotyping of activated leukocytes cultured with IVIg, we hypothesized that biomarkers of efficacy of IVIg may be found on multiple leukocyte populations detected in peripheral blood. This study reports immunophenotyping of major leukocyte populations aimed at identifying changes in leukocyte surface marker expression during IVIg treatment. Markers altered by IVIg treatment were then tested for association with clinical efficacy. The data provide evidence that immune phenotyping before and after IVIg treatment can be used to distinguish responders from nonresponders, and suggest targetingspecific markers and pathways for monitoring clinical response to IVIg in CIDP is feasible.
| METHODS
| Ethical review
Recruitment of CIDP patients in New South Wales was approved by the Sydney Local Health District (RPAH Zone) HREC, and in Victoria by individual institutional HRECs. All study participants gave informed consent.
| CIDP patients
Newly diagnosed (IVIg-naïve) patients (n = 7) and established (IVIgexperienced) patients (n = 14) were examined over the course of two consecutive IVIg treatment cycles. Diagnosis was by clinical and electrophysiological criteria (typical or atypical, sensory and motor, pure motor, or sensory ataxic) according to European Federation of Neurological Societies/Peripheral Nerve Society guidelines ( Van den Bergh et al., 2010) . Inclusion and exclusion criteria for newly diagnosed CIDP were as used for the ICE trial (Hughes et al., 2008) , excepting patient N9 with sensory CIDP. One patient (E14) received low-dose prednisolone (12 mg/day) and methotrexate (20 mg/week); no other patient received steroids.
| IVIg treatment
The two treatment cycles were included, according to patient group:
(1) induction and initial maintenance cycles in newly diagnosed patients and (2) two maintenance cycles in patients on established dose-titrated regimens. Standard-of-care IVIg induction dosing was 2 g/kg over 3-5 consecutive days; individually optimized maintenance doses ranged from 0.4 to 1 g/kg every 2-4 weeks according to the Australian guidelines (National IVIg Criteria Review Working Group, 2012).
| Blood collection and clinical assessment
Blood samples were collected prior to IVIg infusion (day 0) and on day 7 during each cycle, and leukocyte marker expression was quantified by flow cytometry. Clinical scores were measured at the start and end of each treatment cycle. For the adjusted INCAT disability score (Hughes et al., 2001 ), a clinically meaningful change was defined as one point (change between 0 and 1 for upper limb function was not clinically significant in the adjusted INCAT scale). For the Medical Research Council (MRC) sum score (Kleyweg, van der Meche, & Schmitz, 1991) , a two-point change was determined to be clinically meaningful. Response in newly diagnosed patients was defined as at least 1 INCAT point improvement during the induction cycle and stable or improved in the second. Patient N9, with a predominantly sensory deficit, was also assessed by the INCAT sensory sum score (Merkies, Schmitz, van der Meche, & van Doorn, 2000) . Patients responding to established IVIg regimens were scrutinized for response versus relapse during individual treatment cycles, according to stable versus a clinically meaningful deterioration in either neurological score as defined above.
| Full blood counts and flow cytometry panels
Full blood counts were performed on a CellDyn Ruby automated counter (Abbott Diagnostics, Lane Cove, NSW, Australia) using EDTA-anticoagulated blood. Whole blood flow cytometry was performed on heparinized blood. Antibody clones chosen for the leukocyte markers are listed in Table 3 , and all flow cytometry reagents were sourced from BD Biosciences (North Ryde, NSW, 
| Statistical analysis
Statistical analysis was performed using Prism software (GraphPad, San Diego, CA, USA). An initial screen of markers influenced by 
| RESULTS
| Clinical response to IVIg treatment
On the expectation that clinical response could be determined in new CIDP patients after only two IVIg treatment cycles (Hughes et al., 2008) , the two initial treatment cycles were used to deter- (Table 2) , although mean lymphocyte count tended to be higher in established patients that relapsed.
| Leukocyte markers influenced by IVIg treatment
The effect of IVIg treatment on circulating leukocyte populations was screened across a wide range of surface antigens representing both subpopulation and functional markers. Multiple redundant markers were tested because it was not known which would be detectable in peripheral blood during an in vivo response to IVIg, compared to our preliminary data from cultured leukocytes. (Table 4) .
Correction for multiple testing in these markers using Bonferroni correction within each leukocyte population resulted in an adjusted level of significance, indicated in Table 4 . If a conservative correction was based on all 13 markers, the adjusted level required for significance was p = .0038, and only four markers remained significant ( (Fig. 1) . Decreased CD16 + mDCs in responders provided sensitivity for predicting outcome (100%; 95% CI = 80.5-100), but specificity was weak (Fig. 1B) , also driving down expression in some relapsing patients. However, the magnitude of decreased CD16 + mDCs correlated with improved neurological disability scores (MRC and INCAT; Fig. 1C ).
The MRC sum score defined relapse in established patients, whereas the INCAT generally defined nonresponse in new patients ( inflammatory mDCs between treatment cycles is a possible cause of ongoing inflammation in CIDP requiring life-long IVIg treatment.
| DISCUSSION
This study confirmed some of the known immunomodulatory action immunomodulatory changes, including inhibitory Fcγ receptor expression, or autoreactive T-cell populations (Klehmet et al., 2015) , (Park et al., 2014) . The observed decrease in follicular helper T cells after IVIg may reduce autoantibody production as well as macrophage activation pathways (Schmitt, Bentebibel, & Ueno, 2014; Slight et al., 2013) .
Inhibitory Fcγ receptor-mediated pathways of immunomodulation in B cells and monocytes are considered primary mechanisms of IVIg immunomodulation (Tackenberg et al., 2009) , and was confirmed by data from this study. Expression of CD32b decreased after IVIg on both monocytes and memory B cells, as reported on monocytes in IVIg-treated immune thrombocytopenia (Shimomura et al., 2012) . Downregulation of CD32b on B cells may result from increased CD40 ligation (Zhang et al., 2013) . Alternatively, an increase in the balance of type-2 and regulatory cytokines induced by IVIg treatment may promote CD32b expression (Boruchov et al., 2005) , and transitory CD32b downregulation observed in this study CD32a and CD32b antibodies produced by HMT and PMH (Ramsland et al., 2011) . CD32 expression on dendritic cells and monocytes is equivalent to CD32a, and CD32 on B cells is equivalent to CD32b, and therefore data were pooled where appropriate. e Gated on cells negative for lineage markers CD3, CD14, CD19, CD20, CD34, CD56, and CD66. Significance of paired data based on the mean difference in expression before and after treatment. 
